ATC Group: J05AP08 Sofosbuvir

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J05AP08 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J05 Antivirals for systemic use
3 J05A Direct acting antivirals
4 J05AP Antivirals for treatment of HCV infections
5 J05AP08

Active ingredients in J05AP08

Active Ingredient Description
Sofosbuvir

Sofosbuvir is a pan-genotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.

Related product monographs

Title Information Source Document Type  
SOVALDI Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.